| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0399-8320(04)95213-X |
| P698 | PubMed publication ID | 15671931 |
| P50 | author | Patrick Marcellin | Q89798262 |
| P2093 | author name string | Tarik Asselah | |
| Corinne Castelnau | |||
| Marie-Pierre Ripault | |||
| Nathalie Boyer | |||
| P2860 | cites work | Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B | Q28212394 |
| Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group | Q28241816 | ||
| Hepatitis B virus infection--natural history and clinical consequences | Q29617961 | ||
| Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy | Q31431901 | ||
| Tolerability of treatments for viral hepatitis | Q34289643 | ||
| Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial | Q35359761 | ||
| Interferon-alpha for HBeAg-positive chronic hepatitis B. | Q35621670 | ||
| Results of lamivudine trials in Asia | Q35621678 | ||
| Hepatitis B virus resistance to antivirals: clinical implications and management. | Q35621690 | ||
| Immunomodulatory drugs and therapeutic vaccine in chronic hepatitis B infection | Q35621705 | ||
| Treatment of HBeAg-negative chronic hepatitis B with interferon or pegylated interferon | Q35621713 | ||
| A phase II dose-escalating trial of clevudine in patients with chronic hepatitis B. | Q39128672 | ||
| Hepatitis C virus infection, alpha interferon therapy and thyroid dysfunction | Q40443039 | ||
| Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). | Q40751014 | ||
| A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. | Q42541246 | ||
| A pilot study of recombinant interferon beta-1a for the treatment of chronic hepatitis C. | Q43029613 | ||
| Interleukin 2 treatment does not modify hepatitis B or C replication in human immunodeficiency virus-infected patients: results from a randomized control trial | Q43036021 | ||
| Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants | Q43504458 | ||
| Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study | Q43599844 | ||
| Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy | Q43629454 | ||
| Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. | Q43695474 | ||
| Sequential treatment with lamivudine and interferon monotherapies in patients with chronic hepatitis B not responding to interferon alone: results of a pilot study | Q43722498 | ||
| Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection. | Q43722501 | ||
| Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter, randomized trial | Q43760703 | ||
| Lamivudine and alpha-interferon in combination long term for precore mutant chronic hepatitis B. | Q43818679 | ||
| Clinical trial of lamivudine in children with chronic hepatitis B. | Q44010592 | ||
| Lamivudine/interferon combination therapy in anti-HBe positive chronic hepatitis B patients: a controlled pilot study | Q44014358 | ||
| Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease | Q44042298 | ||
| Histological outcome during long-term lamivudine therapy. | Q44269261 | ||
| Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. | Q44329201 | ||
| Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy. | Q44385917 | ||
| Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders. | Q44451380 | ||
| Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1. | Q44507323 | ||
| Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus | Q44709441 | ||
| Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. | Q44709445 | ||
| Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. | Q45061899 | ||
| The efficacy of thymosin in the treatment of chronic hepatitis B virus infection: a meta-analysis | Q45734557 | ||
| Assessment of depression in patients with chronic hepatitis: effect of interferon treatment. | Q50583582 | ||
| Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea | Q57215989 | ||
| Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B | Q58622804 | ||
| Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B | Q59306546 | ||
| Recombinant human γ-interferon in patients with chronic active hepatitis B: Pharmacokinetics, tolerance and biological effects | Q61045650 | ||
| Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study | Q61054098 | ||
| Efficacy and limitations of a specific immunotherapy in chronic hepatitis B | Q62658364 | ||
| Lamivudine as initial treatment for chronic hepatitis B in the United States | Q73098368 | ||
| Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B | Q73308069 | ||
| A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis B | Q73523468 | ||
| The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B | Q73700085 | ||
| Mechanisms of action of interferon and nucleoside analogues | Q75226930 | ||
| Chronic hepatitis B | Q77318153 | ||
| P433 | issue | 12 | |
| P921 | main subject | chronic hepatitis B | Q55779876 |
| P304 | page(s) | 1215-1227 | |
| P577 | publication date | 2004-12-01 | |
| P1433 | published in | Gastroenterologie Clinique et Biologique | Q15756157 |
| P1476 | title | [Treatment of chronic hepatitis B] | |
| P478 | volume | 28 |
Search more.